Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2019 | editorial

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

verfasst von: Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

Fundamental progress has been achieved in the treatment of solid cancers over the last two decades and patients’ long-term outcome has improved accordingly. With monoclonal antibodies, small-molecule tyrosine kinase inhibitors and more recently, immune checkpoint modulators, a plethora of highly active novel drugs has become available. But are truly all patients benefitting from these successes? In an elderly population of breast cancer patients, the HER2-positive subtype was still associated with the worst prognosis as shown in a recent publication [1] despite the excellent survival results achieved within clinical trials [2]. …
Vorheriger Artikel Amazing advances in the field of uro-oncology
Nächster Artikel Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria
Literatur
1.
Bergen ES, Tichy C, Berghoff AS, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat. 2016;157(1):91–9.CrossRef
2.
Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.CrossRef
3.
Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE. Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev Oncol Hematol. 2008;67(3):237–342.CrossRef
4.
5.
Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–92.CrossRef
6.
Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRef
Metadaten
Titel
Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?
verfasst von
Rupert Bartsch
Publikationsdatum
01.12.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00535-6

Weitere Artikel der Ausgabe 4/2019

ASCO 2019: highlights in HER2-positive metastatic breast cancer

  • Open Access
  • review

Current trends in small cell lung cancer management—ASCO 2019 update

  • short review

An update from the 2019 ASCO Annual Meeting

  • editorial

Biomarkers in renal cell carcinoma

  • short review

First-line treatment of metastatic renal cell carcinoma: current standard of care

  • short review

Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?

  • short review